Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer.

Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA.

Int J Gastrointest Cancer. 2006;37(1):7-14.

PMID:
17290076
2.

Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer.

Chiarion-Sileni V, Innocente R, Cavina R, Ruol A, Corti L, Pigozzo J, Del Bianco P, Fumagalli U, Santoro A, Ancona E.

Cancer Chemother Pharmacol. 2009 May;63(6):1111-9. doi: 10.1007/s00280-008-0834-3. Epub 2008 Sep 30.

PMID:
18825381
3.

Preoperative chemotherapy and radiation for advanced esophageal carcinoma: comparison between once a day radiation and hyperfractionation, a single-institution experience.

Nguyen NP, Leonardo JM, Karlsson U, Salehpour M, Vos P, Robiou C, Moran JF, Thomas P, Bullock L, Ludin A, Jendrasiak G, Sallah S.

Am J Clin Oncol. 2002 Aug;25(4):358-64.

PMID:
12151965
4.

Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.

Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP.

Ann Thorac Surg. 2008 Jun;85(6):1930-6; discussion 1936-7. doi: 10.1016/j.athoracsur.2008.01.097.

PMID:
18498797
5.

Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma.

O'Connor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM.

Cancer J. 2007 Mar-Apr;13(2):119-24.

PMID:
17476140
6.

Optimal treatment for localized esophageal cancer still uncertain.

Lord RV.

Am J Gastroenterol. 2000 Jan;95(1):305-7.

PMID:
10638607
7.

Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.

Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD.

Ann Surg Oncol. 2006 Feb;13(2):214-20. Epub 2006 Jan 18.

PMID:
16418887
8.

[Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].

Jiang YY, Wu SX, Zhang P, Xie CY, Wang J, Sun CC.

Zhonghua Yi Xue Za Zhi. 2008 Aug 12;88(31):2171-4. Chinese.

PMID:
19080664
9.

Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.

Roof KS, Coen J, Lynch TJ, Wright C, Fidias P, Willett CG, Choi NC.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1120-8. Epub 2006 May 26.

PMID:
16730135
10.

Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG; Radiation Therapy Oncology Group.; USA Intergroup..

J Clin Oncol. 2007 Aug 20;25(24):3719-25.

PMID:
17704421
11.

A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.

Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, Zuccaro G, Vargo JJ, Dumot JA, Carroll MA.

Am J Clin Oncol. 2007 Apr;30(2):172-80.

PMID:
17414467
12.

Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.

Brunner TB, Rupp A, Melzner W, Grabenbauer GG, Sauer R.

Strahlenther Onkol. 2008 Jan;184(1):15-22. doi: 10.1007/s00066-008-1787-5.

PMID:
18188518
13.

Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.

Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Glück S, Brizel HE, Meredith RF, Berger D, Chen MG, Mendenhall W.

J Clin Oncol. 2008 May 20;26(15):2489-96. doi: 10.1200/JCO.2007.13.7349.

PMID:
18487568
14.

Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.

Wolff K, Wein A, Reulbach U, Männlein G, Brückl V, Meier C, Ostermeier N, Schwab SA, Horbach T, Hohenberger W, Hahn EG, Boxberger F.

Anticancer Drugs. 2009 Mar;20(3):165-73. doi: 10.1097/CAD.0b013e32831f8ec9.

PMID:
19125117
15.

Impact of neoadjuvant therapy of perioperative morbidity in patients with esophageal cancer.

Imdahl A, Schöffel U, Ruf G.

Am J Surg. 2004 Jan;187(1):64-8.

PMID:
14706588
16.

Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.

Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA.

Invest New Drugs. 2006 Mar;24(2):135-40.

PMID:
16502351
17.

A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.

Czito BG, Cohen DP, Kelsey CR, Lockhart AC, Bendell JC, Willett CG, Petros WP, D'Amico TA, Truax R, Hurwitz HI.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1066-72. Epub 2007 Sep 19.

PMID:
17881149
18.

A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.

Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, Xi W, Li H, Jin Y.

Jpn J Clin Oncol. 2009 Sep;39(9):582-7. doi: 10.1093/jjco/hyp058. Epub 2009 Jun 9.

PMID:
19509000
19.

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ.

Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1.

PMID:
18977518
20.

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).

Vestermark LW, Jacobsen A, Qvortrup C, Hansen F, Bisgaard C, Baatrup G, Rasmussen P, Pfeiffer P.

Acta Oncol. 2008;47(3):428-33. doi: 10.1080/02841860701798866.

PMID:
18348002

Supplemental Content

Support Center